Apr, 2024

Global
News / Press Releases
[Press Release for Media and Investors] Astellas Breaks Ground on New €330 Million State-of-the-Art Facility in Tralee, Co. Kerry, Ireland

- Facility will manufacture pharmaceutical products, including innovative antibody drugs
- 600 construction jobs and 100 highly specialised roles in engineering, science, and technology...

Read More
Global
News / Press Releases
[Press Release for Medical and Financial Press] Astellas Receives Positive CHMP Opinion for Enzalutamide in Additional Recurrent Early Prostate Cancer Treatment Setting

-If approved, enzalutamide would become the first and only NHT treatment for metastatic and high risk biochemical recurrent non-metastatic hormone sensitive prostate cancer patient...

Read More

Dec, 2023

Global
News / Press Releases
[Press Release for Media and Investors] Astellas’ Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause Compared to Placebo in Women Considered Unsuitable for Hormone Therapy

Phase 3b DAYLIGHT study being presented at ESG 2023 demonstrated fezolinetant 45 mg achieved statistically significant reductions in the frequency and severity of moderate to severe...

Read More
Global
News / Press Releases
[Press Release for Media and Investors] Astellas’ VEOZA® (fezolinetant) Approved by European Commission for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

First-in-class1,2,3treatment option to manage the number and intensity of hot flashes and night sweats

 

TOKYO, December 11, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO...

Read More

Oct, 2023

Global
News / Stories
[PRESS RELEASE FOR JOURNALISTS AND INVESTORS] Astellas Receives Positive CHMP Opinion for fezolinetant
chmp_opinion_eu_social

Fezolinetant is an investigational nonhormonal treatment for vasomotor symptoms (VMS) associated with menopause

More than half of women ages 40 to 64 worldwide experience VMS, with...

Read More
Nothing Found

Unfortunately, we weren't able to find a match for you.

Nothing Found

Unfortunately, we weren't able to find a match for you.

 

MAT-GB-NON-2023-00232 October 2023

 

The Astellas EST-C Communications team
will respond to emails from journalists.
For general media enquiries,
please email [email protected].